The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global cough syrup market exhibited moderate growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 4% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Cough syrup is a combination drug that is used to provide temporary relief from cough, common cold, hay fever and other respiratory allergies. It is manufactured using non-opioid cough suppressants, expectorants and antihistamine compounds to block the symptoms. The suppressants aid in alleviating the symptoms of dry cough by minimizing the activity of the cough reflex and reducing the urge to cough. The expectorants aid in treating cough with mucus by loosening the mucus, thereby making it easier to expel from the body. The antihistamines are used to relieve cough caused by minor throat or airway irritation. Cough syrups are usually prescribed by doctors or are available over-the-counter (OTC) in pharmacy stores in a wide variety of flavors, such as cherry, orange, honey and bubblegum.
The increasing prevalence of upper respiratory tract infection (URTI) and other respiratory disorders across the globe is one of the key factors driving the growth of the market. Moreover, the rising geriatric population, which is more susceptible to such ailments, is providing a thrust to the market growth. Cough syrup is primarily used for the treatment of dry cough developed due to the prolonged exposure to poor air quality, tobacco and indoor smoke and air pollution. In line with this, the rising health consciousness among the masses and convenient product availability in pharmacies and general stores are also contributing to the growth of the market. Additionally, various product innovations, such as the development of cough syrups with minimal side effects, are acting as other growth-inducing factors. Product manufacturers are developing variants fortified with natural herbs and ingredients with immunity-boosting effects. Other factors, including rising expenditure capacities of the consumers, along with significant growth in the pharmaceutical industry, are anticipated to drive the market toward growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global cough syrup market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on product type, age group and distribution channel.
Breakup by Product Type:
Breakup by Age Group:
Breakup by Distribution Channel:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Acella Pharmaceuticals LLC, Bayer AG, GlaxoSmithKline PLC, Johnson & Johnson, Pfizer Inc., Prestige Consumer Healthcare Inc., Reckitt Benckiser Group PLC, Sanofi, Sun Pharmaceutical Industries Limited and The Procter & Gamble Company.
|Base Year of the Analysis||2020|
|Segment Coverage||Product Type, Age Group, Distribution Channel, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Acella Pharmaceuticals LLC, Bayer AG, GlaxoSmithKline PLC, Johnson & Johnson, Pfizer Inc., Prestige Consumer Healthcare Inc., Reckitt Benckiser Group PLC, Sanofi, Sun Pharmaceutical Industries Limited and The Procter & Gamble Company|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at